Oct 14, 2020
New Data for Zepzelca(TM) (lurbinectedin) to be Presented at IASLC 2020 North America Conference on Lung Cancer
Jun 15, 2020
Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca(TM) (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer
Apr 28, 2020
PharmaMar Has Announced That the Spanish Medicines Agency Has Authorized the APLICOV-PC Clinical Trial With Aplidin® (Plitidepsin) for the Treatment of Patients With COVID-19
Jan 22, 2020
PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period
Dec 19, 2019
PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S.
Oct 14, 2019
STA To Market Sarcoma Drug In Australia, New Zealand And SE Asia Following License Deal
Aug 19, 2019
PharmaMar will submit NDA for lurbinectedin under accelerated approval in SCLC in the USA
Oct 19, 2018
Sylentis, PharmaMar Group, Announces the End of Patient Recruitment for its HELIX Trial
Sep 24, 2018
PharmaMar Presents the Overall Survival Data From the Phase I/II Study of lurbinectedin in Combination With Doxorubicin for Relapsed Small Cell Lung Cancer
Sep 07, 2018
PharmaMar is Announcing its Intention to Conduct a Registered Public Offering of American Depositary Shares
Sep 06, 2018
PharmaMar Will Present the Results of the Phase I/II Study With Lurbinectedin in Combination With Doxorubicin in Relapsed Small-cell Lung Cancer During the IASLC World Conference
Aug 03, 2018
The U.S. Food and Drug Administration (FDA) Has Granted Orphan Drug Designation to PharmaMar's Lurbinectedin
Jul 31, 2018
PharmaMar Announces That the ATLANTIS Study Has Reached the Goal of Patient Recruitment
Jul 27, 2018
PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis® in the Nordic Countries and Eastern Europe
Jun 26, 2018
PharmaMar and Chugai Agree to Terms for Early Termination of the License Agreement for Zepsyre® in Japan
Jun 11, 2018
PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® With Pint Pharma International
Jun 05, 2018
PharmaMar Presents in Oral Session at ASCO: The ADMYRE Study's Adjusted Overall Survival With Plitidepsin
Jun 04, 2018
PharmaMar Presents New Results with Lurbinectedin as a Single Agent in Patients with Recurrent Small-cell Lung Cancer at ASCO 2018
May 29, 2018
Positive Recommendation of IDMC to Zepsyre® to Continue the Phase III Trial Within Small-cell Lung Cancer (ATLANTIS)
May 17, 2018
PharmaMar Announces Data Presentations For Both Its Molecules Yondelis® and Lurbinectedin at ASCO 2018